MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th,

MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17t

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq:

COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil pr

– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor pro

The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in As

Assembly Biosciences, Inc. (ASMB) reached a significant support level, and could be a good pick for

EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by i

Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and lowe

LQDT, IA and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25th, 202

IA, ASMB, LQDT, OFG and TGT have been added to the Zacks Rank #1 (Strong Buy) List on August 25th, 2

LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2

MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st,

Does Assembly Biosciences (ASMB) have what it takes to be a top stock pick for momentum investors? L

The average of price targets set by Wall Street analysts indicates a potential upside of 40.7% in As

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences is maintained at a 'Buy' rating, driven by pipeline advancement and a strong ca

Assembly Biosciences (ASMB) came out with a quarterly loss of $0.2 per share versus the Zacks Consen

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.20) per share which beat the ana

– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary

Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and rais

Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy duri

Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maint

US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumpe

Zoom Communications Inc shares rise after strong financial results and increased buyback authorizat

Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics

"We are excited to expand the ABI-6250 program into PBC and PSC, where there remains significant

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.54) per share which beat the ana

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB)

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB)

Scholastic Corp (NASDAQ: SCHL) rose 10.7% on Friday after reporting better-than-expected earnings an

Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings of $1.30 per share which beat the ana

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activi

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB)

Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (NASDAQ:ASMB), today announced G

Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and rais

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.72) per share which beat the ana

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutic

  Monday saw 196 companies set new 52-week lows.

  Wednesday saw 219 companies set new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.